BrainsWay Ltd. (BWAY) has a MoatMap StockRank of 87/100 based on Quality (72/100), Value (15/100), and Momentum (86/100) factor scores. The current signal is STRONG BUY. BrainsWay develops non-invasive neurostimulation treatments. Despite interesting medical technology, it is a small-cap medical device company with volatile cash flows and no direct connection to our high-conviction macro themes.
BrainsWay Ltd. develops and commercializes advanced non-invasive brain stimulation technology, Deep Transcranial Magnetic Stimulation (Deep TMS), for treating mental health disorders like depression and OCD. As a pioneer in Deep TMS technology, it holds FDA clearance for specific psychiatric conditions and benefits from a patented technology offering a unique treatment modality. BrainsWay is a specialized medical device company at the forefront of non-invasive neurological treatments, focused on expanding its proprietary Deep TMS platform's clinical applications.
| Price | $14.43 |
| Market Cap | $637M |
| P/E (TTM) | 64.86 |
| P/E (Forward) | 30.58 |
| Price/Book | 7.19 |
| Return on Equity | 12.6% |
| Return on Invested Capital | 10.9% |
| Debt/Equity | 8.85 |
| Gross Margin | 75.5% |
| Operating Margin | 12.9% |
| Revenue Growth | 34.6% |
| Free Cash Flow | $3M |
BrainsWay Ltd. operates in the Medical Devices industry, part of the Healthcare sector (Israel).